A Phase Ib Study of the Selective PKC- Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL
Status:
NOT_YET_RECRUITING
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
A Phase Ib Study of the Selective PKC- Inhibitor MS-553 in Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma